Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SP306 (in Japan), Tdap
Adacel · 1 trial · 3 indications
Solicited injection site reactions: Pain, itchiness, erythema (redness), and swelling. Solicited systemic reactions: Headache, body ache and muscle weakness, tiredness, chill, nausea, vomiting, rash, itchiness, anorexia, sore and swollen joints, diarrhea, lymph node swelling, and fever (temperature).
| Arm | Type | Description |
|---|---|---|
| Study Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis) | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria : * Male or female (not pregnant) from 18-45 years of age. * Healthy, with no current illnesses. * Have not been immunized against diphtheria, pertussis and tetanus in the past 5 years. * Women of childbearing age will agree to use birth control during the study. * In good health...
Adacel is a vaccine developed by Sanofi for the prevention of diphtheria, tetanus, and pertussis. It is a tetanus, reduced diphtheria toxoid, and acellular pertussis vaccine. Adacel is also known as Adacel (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis). It is used in infectious disease prevention.
Adacel is used for immunization against diphtheria, tetanus, and pertussis. It is indicated for active booster immunization against these three diseases. The vaccine is designed to protect individuals from diphtheria, a serious bacterial infection, as well as tetanus and pertussis.
Adacel is made by Sanofi, a global pharmaceutical company. Sanofi trades under the ticker symbol SNY. The company develops and manufactures Adacel as part of its vaccine portfolio. Sanofi is the developer responsible for the clinical development and production of Adacel.
Adacel is in Phase 3 clinical development. A completed Phase 3 trial, NCT01040052, assessed the safety of Adacel vaccine. The trial enrolled 30 participants in Vietnam. Adacel is an investigational vaccine and has been studied in a Phase 3 trial for safety.
Adacel has been studied in a completed Phase 3 clinical trial, NCT01040052, titled A Study to Assess the Safety of Adacel Vaccine. The trial enrolled 30 participants aged 18 years and older in Vietnam. It was an uncontrolled, non-randomized study that included healthy volunteers.